rexulti.com — September 2026 traffic, keywords & AI visibility

rexulti.com draws an estimated 51,500 visits a month from search engines. 95% of it is organic, so it leans very little on paid search. Spread across 589 ranking keywords, that averages roughly 83 organic visits per keyword.

On our AI visibility scale rexulti.com earns 67 of 100 points, a grade C. It takes full marks for LLMS.txt and Structured data. The biggest gap is SEO health, at 0 of 20 points (0/100), worth 20 points if closed. It also loses points on Crawlability (0/10) and Company profile (22/25).

The llms.txt on rexulti.com runs to 78 lines (5,076 characters) across 12 sections, last generated in June 2026. It introduces the site as "Rexulti: For Adults with Depression and Schizophrenia". It tells AI engines the business works in Healthcare, Life Sciences & Wellness; Research, Science & Deep Tech; Professional & Business Services; Pharmaceutical Manufacturing; and Mental Health Treatment. It describes 2 products, including Rexulti (brexpiprazole) for Major Depressive Disorder and Rexulti (brexpiprazole) for Schizophrenia. Services it lists include Patient Education Resources, Healthcare Professional Resources and Support Programs Information. The audience it names is Patients diagnosed with Major Depressive Disorder or Schizophrenia, aged Adults (Global (where approved)). Technologies it mentions include HTML5, CSS3, JavaScript and SSL/TLS. The keywords it claims start with "Rexulti", "mental health", "depression treatment" and "schizophrenia medication".

# Rexulti: For Adults with Depression and Schizophrenia

## About
Rexulti is a prescription medication specifically developed to address the complex challenges faced by adults living with major depressive disorder (MDD) and schizophrenia. It represents a significant advancement in psychopharmacology, offering a unique mechanism of action designed to help manage the debilitating symptoms associated with these serious mental health conditions. The primary goal of Rexulti is to improve patients' overall quality of life by alleviating symptoms such as mood disturbances, cognitive impairments, and psychotic episodes, enabling them to engage more fully in daily activities and personal relationships.

Understanding the profound impact of depression and schizophrenia on individuals and their families, the development of Rexulti involved extensive research and rigorous clinical trials. These studies were crucial in demonstrating its efficacy and safety profile, leading to its approval by regulatory bodies. The medication is intended to be part of a comprehensive treatment plan, often alongside psychotherapy and other supportive measures, guided by a qualified healthcare professional. The website serves as a vital resource, providing essential information for patients, caregivers, and healthcare providers about the medication, its benefits, potential side effects, and proper usage.

This

Google lists rexulti.com for about 589 keywords, which together bring an estimated 48,900 organic visits a month.

The latest technical audit of rexulti.com scored 0 out of 100 overall. The audit makes 12 recommendations in all, and 4 of the 4 listed first are rated high priority or critical.

Rexulti's company profile names https://www.abilify.com, https://www.eskalith.com, https://www.zoloft.com and https://www.prozac.com as competitors. Its own llms.txt adds https://www.lithobid.com and https://www.latuda.com. Outside its market, the domains ranked closest to it in our worldwide ranking are judoinside.com, neuroth.com, teuida.net and jj.ac.kr.

https://www.abilify.com

https://www.eskalith.com

https://www.zoloft.com

https://www.prozac.com

https://www.lithobid.com

https://www.latuda.com